AUROBINDO PHARMA
|
The Current P/E Ratio of AUROBINDO PHARMA is 18.67.
Share Price | ₹1,156.9 | Jan 29,2025 |
Market Cap | ₹67,192.8 Cr | |
Earnings-TTM | ₹3,598.8 Cr | TTM-Consolidated Results |
Price/Earnings | 18.67x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of AUROBINDO PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹67,192.8 Cr] as on Jan 29,2025
(/) Earnings [ ₹3,598.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 18.67x ]
Thus, for AUROBINDO PHARMA , the investors are currently willing to pay 18.67 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of AUROBINDO PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of AUROBINDO PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of AUROBINDO PHARMA
PE Ratio Performance Analysis for AUROBINDO PHARMA
- AUROBINDO PHARMA 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 13.77x.
- AUROBINDO PHARMA 's operated at median p/e ratio of 14.8x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, AUROBINDO PHARMA 's p/e ratio peaked in Mar2024 at 20.12x.
- AUROBINDO PHARMA 's p/e ratio hit its five-year low in Mar2020 of 8.51x.
How does AUROBINDO PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
AUROBINDO PHARMA | 3,598.83 | 18.67 | 67,192.8 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,136.50 | 37.42 | 416,692.0 |
CIPLA LTD | 5,000.43 | 23.00 | 115,000.0 |
DR REDDYS LABORATORIES LTD | 5,428.60 | 18.17 | 98,616.4 |
ZYDUS LIFESCIENCES LTD | 4,298.90 | 21.83 | 93,841.4 |
DIVIS LABORATORIES LTD | 1,836.00 | 81.27 | 149,215.0 |
MANKIND PHARMA LTD | 2,050.73 | 49.85 | 102,232.0 |
TORRENT PHARMACEUTICALS LTD | 1,862.00 | 61.06 | 113,701.0 |
LUPIN LTD | 2,651.94 | 35.57 | 94,337.9 |
ABBOTT INDIA LTD | 1,284.66 | 42.14 | 54,136.1 |
ALKEM LABORATORIES LTD | 2,160.96 | 27.69 | 59,830.3 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs AUROBINDO PHARMA 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.17x |
Max industry PE | 81.27x |
Median industry PE | 35.57x |
Average industry PE | 37.88x |
You may also like the below Video Courses